671. Why Has There Been So Little Progress on Alzheimer’s Disease?

Episode Summary

Executive Summary: The episode investigates long-standing problems in Alzheimer’s research, focusing on the amyloid hypothesis and evidence of manipulated data in influential papers and drug development efforts. Reporter Charles Piller and neuroscientist Matthew Schrag describe how flawed studies, weak oversight, and institutional incentives may have distorted the field, while arguing for broader, more rigorous approaches to Alzheimer’s that include vascular health and waste clearance.

Main Topics: Alzheimer’s as a major public-health crisis (Priority: 5/5): The episode frames Alzheimer’s as widespread, devastating, and scientifically unresolved despite enormous spending and recent FDA blood-test approvals for earlier detection. The amyloid cascade hypothesis and its limits (Priority: 5/5): Schrag explains the dominant theory that beta-amyloid plaques trigger Alzheimer’s, but argues the disease is likely far more complex than a single-cause model. Investigations into research misconduct (Priority: 5/5): Piller and Schrag detail image manipulation, data irregularities, and questionable practices in papers tied to influential Alzheimer’s findings and drug development. Cassava Sciences and simufilam (Priority: 4/5): The show recounts whistleblower concerns, forensic review, and later legal/regulatory outcomes surrounding Cassava’s experimental Alzheimer’s drug and collaborator Hao Yan Wang. Retractions and the collapse of influential papers (Priority: 4/5): A highly cited 2006 Nature paper and other work linked to Sylvain Lesné, Karen Ashe, and Othman Grebe are discussed as examples of how flawed data can shape a field for years. Institutional incentives and regulatory capture (Priority: 4/5): Piller argues that universities, journals, NIH, and FDA processes can be too slow or conflicted, allowing bad science to persist and shaping drug approvals and careers. Future directions: beyond amyloid (Priority: 4/5): Schrag advocates a broader model centered on failed waste clearance and blood-vessel health, suggesting combinations of treatments and stronger prevention could matter more.

Key Arguments: Alzheimer’s research has absorbed tens of billions of dollars, yet no treatment clearly arrests or reverses the disease, suggesting that the field’s dominant framework may be incomplete or wrong. The amyloid hypothesis may capture part of the disease, but not enough; Alzheimer’s likely involves multiple interacting factors, including blood-vessel disease, inflammation, and waste clearance. Some influential Alzheimer’s papers appear to contain manipulated images or other irregularities that may have overstated results and misled subsequent research and drug development. Weak oversight by universities and government review bodies can allow questionable research to persist for years, especially when institutions are reluctant to police their own. Cassava Sciences became a case study in how weak or suspect foundational science can support a drug program until whistleblowers and forensic analysis expose the problems. Piller argues that criticism of bad science is not anti-science; instead, it is necessary to protect the scientific record and restore trust. Schrag proposes that blood-vessel health and aggressive blood-pressure control may be a more promising preventive avenue than amyloid-only strategies. The field’s incentives—career prestige, funding, and institutional momentum—can create resistance to changing theories even when clinical results remain underwhelming.

Data Points: U.S. Alzheimer’s cases: more than 7 million - Estimated number of Americans living with Alzheimer’s disease, mostly over age 65. Duration before symptoms: up to 20 years - Alzheimer’s can develop long before obvious symptoms appear. NIH Alzheimer’s/dementia research spending: around $4 billion a year - Current annual NIH spending cited on Alzheimer’s and dementia research. NIH Alzheimer’s/dementia research spending a decade ago: around $1 billion a year - Shows the increase in federal research investment over the past decade. Funding rank: second only to cancer - Alzheimer’s/dementia research funding is described as second-highest at NIH. FDA medical examiners who later joined industry: 11 of 16 - Piller cites this as evidence of regulatory capture and a revolving door at the FDA. Cassava settlement with SEC: $40 million - SEC settlement over misleading investors about simufilam’s effectiveness. Influential papers reviewed on Masliah: 132 of 800 - Piller and experts screened 132 of roughly 800 papers for image irregularities. Masliah dossier length: 300 pages - Compiled documentation of suspected image and data problems in Eliezer Masliah’s work. Year of first formal Alzheimer’s documentation: 1906 - Alois Alzheimer is credited with the disease’s first formal documentation. Year of influential Nature paper: 2006 - The paper 'A Specific Beta Amyloid Protein Assembly in the Brain Impairs Memory' is discussed as highly influential. Year of rabbit paper: 2006 - Schrag’s early co-authored rabbit study on cholesterol and plaques. Year rabbit paper retracted: 2023 - The 2006 rabbit paper by Grebe, Schrag, and others was later retracted. Year Lesné investigation concluded with retirement: 2025 - Piller says Lesné retired/resigned after investigations into his work.

Pivotal Quotes: "No one's getting better with these drugs. Every scientist who works with them, every clinician, will say the same. If they don't, they're lying." — Matthew Schrag: On the limitations of anti-amyloid Alzheimer’s drugs and why the field needs a new direction. "Cheaters tend to cheat." — Charles Piller: On the pattern that once one paper or scientist shows misconduct, broader problems often emerge across related work. "trust must be earned." — Charles Piller: On public skepticism toward science and the need for institutions to prove reliability through transparency and accountability.

Implications: Listeners are left with a cautionary view of Alzheimer’s science: major theories may be incomplete, some landmark findings may be compromised, and institutions need stronger oversight. Future progress likely depends on broader biology, better prevention, and more rigorous validation of results.